Program Title:  Anemia and the Use of Hematopoietic Growth Factors

This activity is no longer availale for CME credit.

Release Date: 12/1/2005

Valid Through: 12/31/2006

Target Audience

This activity is intended for healthcare professionals involved in the management of chemotherapy-induced anemia.

Learning Objectives

After completing this educational activity, participants should be better able to:

• Propose a therapeutic treatment of anemia in the patient undergoing chemotherapy by comparing the two hematopoietic growth factors, epoetin alfa and darbepoetin alfa, in terms of transfusion requirements and hemoglobin levels
• Assess the effectiveness and feasibility of extended-dosing schedules of epoetin alfa and darbepoetin alfa based on individual patient considerations
• Predict the potential benefits of primary prophylaxis with hematopoietic growth factors in those patients undergoing dose-dense chemotherapy regimens
  

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Creative Educational Concepts, Inc. (CEC) and OncoEd, Inc. CEC is accredited by the ACCME to provide continuing medical education for physicians.

CEC designates this educational activity for a maximum of 0.5 category 1 credits toward the AMA Physicians' Recognition Award. Each physician should claim only those credits that he or she actually spent in the activity.

CEC is an equal opportunity/affirmative action institution.

Fee:There is no fee for this activity.

Instructions for Participation

This activity was released in December 1, 2005, and will be valid through December 31, 2006. There are no fees for participating and receiving credit for this activity. To successfully complete this activity, participants must do the following:

• Read the target audience, learning objectives, and author disclosures.
• Study the educational activity online or printed out.
• Read, complete, and submit answers to the post test questions and evaluation questions online and click "submit" when finished.
• After clicking "submit," your online certificate will be made available for you to view and print.

Hardware/Software Requirements

This Website requires version 4.x browsers or higher from Microsoft or Netscape. It has been optimized for Microsoft Browsers.

Privacy and Confidentiality

CancerConsultants is committed to respecting your privacy. We've structured our Web site so that you can visit CancerConsultants on the Web without identifying yourself or revealing any personal information. If you choose to provide us personally identifiable information, you can be assured that it will only be used to support your relationship with CancerConsultants.

On some CancerConsultants Web pages, you can make requests, and register to receive materials. The types of personal information collected at these pages are name and contact information. In order to tailor our subsequent communications to you and continuously improve our products and services, we may also ask you to voluntarily provide us with information regarding your experience with cancer, personal or professional interests, demographics and contact preferences.

CancerConsultants is committed to ensuring the security of your information. To prevent unauthorized access, maintain data accuracy, and ensure the appropriate use of information, we have put in place appropriate physical, electronic, and managerial procedures to safeguard and secure the information we collect online.

CancerConsultants has links to many other sites and cannot ensure the privacy or security of information you provide to the linked site.

If you have comments or questions about our privacy policy, please send them to this email address: mail@cancerconsultants.com.

Faculty and Disclosures

CEC is committed to the provision of CME that is balanced, objective, and evidence based. CEC adheres to Accreditation Council for Continuing Medical Education (ACCME) Essentials and Standards. Accordingly, all parties involved in content development have disclosed any real or apparent conflicts of interest relating to the topics of this educational activity and the disclosure summary follows. CEC has established mechanisms to resolve conflicts of interest should they arise. Participants in CEC CME programs are afforded the opportunity to provide feedback on the quality of individual programs.

Author: Lee Schwartzberg, MD, FACP
Disclosure: Dr. Schwartzberg has disclosed that he is on the speakers' bureau for Amgen, Inc..

Editor: Adam C. Tanous, Director and Managing Editor, OncoEd, Inc.
Disclosure: Mr. Tanous has no relevant financial interests to disclose.

Disclaimer

Notwithstanding any language to the contrary, nothing contained herein constitutes, nor is intended to constitute, an offer, inducement, promise, or contract of any kind. The data contained herein are for informational purposes only and are not represented to be error free. Any links to non-CEC information are provided as a courtesy. They are not intended to constitute, nor do they constitute, an endorsement of the linked materials by CEC.

Investigational and/or off-label use of commercial products and devices

CEC requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

Supporters

This activity is supported by an unrestricted educational grant from Amgen.